Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Aug 6, 2026 (2 months ago)

Nexterone (amiodarone HCI) (Amiodarone Hydrochloride)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Nexterone (amiodarone HCI), 360 mg/200 mL (1.8 mg/mL) in GALAXY Single-Dose Container, sterile, Nonpyrogenic, iso-osmotic solution in Dextrose, Baxter Healthcare Corporation, Deerfield, IL 60015, Made in the USA, NDC 43066-360-20.

Affected NDC 43066-0360-20

Compare with the code on your package — it is the most precise check available.

Drug: Amiodarone

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Nexterone
amiodarone hydrochloride
NDC 43066-0360
1.8 mg/mL Injection, Solution
Intravenous
Baxter Healthcare Corporation Rx
Recalling firm
Baxter Healthcare Corporation
NDC code
43066-360-20
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0814-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Amiodarone recalls

See all
Class I · High risk

Amiodarone Hydrochloride Injection

Labeling: Label Mix-Up; potential for cartons labeled as Tranexamic Acid Injection, USP to contain vials of Amiodarone HCl Injection, USP and cartons labeled as Amiodarone HCl Injection, USP to contain vials of Tranexamic Acid Injection, USP.

Terminated Labeling / mix-up Mylan Institutional LLC NDC 67457-153-99 D-1575-2020
Class I · High risk

Nexterone (amiodarone HCl)

Presence of Particulate Matter:Particulate identified as polyethylene, the primary constituent of the film and ports used to manufacture the bag in which product is packaged

Terminated Particulate / foreign matter Baxter Healthcare Corporation NDC 43066-150-10 D-0573-2018

Other recalls by Baxter Healthcare Corporation

All 2026 recalls
Class I · High risk

Dextrose Injection

Presence of Particulate Matter: particulate matter identified as stainless steel particles in the solution.

Ongoing Particulate / foreign matter Baxter Healthcare Corporation NDC 00338-0719-06 D-0850-2026
Class II · Moderate risk

Daptomycin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-0718-12 D-0821-2026